Version 1
: Received: 22 May 2024 / Approved: 23 May 2024 / Online: 23 May 2024 (12:34:29 CEST)
How to cite:
Tat, V. Y.; Huang, P.; Khanipov, K.; Tat, N. Y.; Tseng, C.-T. K.; Golovko, G. Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. Preprints2024, 2024051544. https://doi.org/10.20944/preprints202405.1544.v1
Tat, V. Y.; Huang, P.; Khanipov, K.; Tat, N. Y.; Tseng, C.-T. K.; Golovko, G. Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. Preprints 2024, 2024051544. https://doi.org/10.20944/preprints202405.1544.v1
Tat, V. Y.; Huang, P.; Khanipov, K.; Tat, N. Y.; Tseng, C.-T. K.; Golovko, G. Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. Preprints2024, 2024051544. https://doi.org/10.20944/preprints202405.1544.v1
APA Style
Tat, V. Y., Huang, P., Khanipov, K., Tat, N. Y., Tseng, C. T. K., & Golovko, G. (2024). Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. Preprints. https://doi.org/10.20944/preprints202405.1544.v1
Chicago/Turabian Style
Tat, V. Y., Chien-Te Kent Tseng and George Golovko. 2024 "Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study" Preprints. https://doi.org/10.20944/preprints202405.1544.v1
Abstract
Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity score-matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1-30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.
Keywords
COVID-19; Interferons; Treatments; Sequelae
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
*
,
*
